Literature DB >> 23717034

Epoprostenol: flushing or erythroderma?

María Luisa Martínez-Martínez1, Eduardo Escario-Travesedo, Ana Nuñez-Ares, Syong Hyun Nam-Cha, María Rodríguez-Vázquez, Juan Gabriel Córdoba-Soriano, Rafaela Sánchez-Simón-Talero.   

Abstract

Entities:  

Year:  2013        PMID： 23717034      PMCID： PMC3662936          DOI： 10.5021/ad.2013.25.2.271

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


× No keyword cloud information.
  5 in total

1.  Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Authors:  D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

2.  Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

Authors:  Vallerie V McLaughlin; Alicia Shillington; Stuart Rich
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

3.  Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.

Authors:  Sarah A Myers; Gregory S Ahearn; M Angelica Selim; Victor F Tapson
Journal:  J Am Acad Dermatol       Date:  2004-07       Impact factor: 11.527

4.  Severe erythroderma as a complication of continuous epoprostenol therapy.

Authors:  Gregory S Ahearn; M Angelica Selim; Victor F Tapson
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

5.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Authors:  R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.